Complete response as an intermediate end point in patients receiving salvage systemic therapy for urothelial carcinoma

Clinical Genitourinary Cancer

Volumn 13, Issue 2, 2015, Pages 185-192

  Sonpavde, Guru ^a   Pond, Gregory R ^b   Rosenberg, Jonathan E ^c   Bajorin, Dean F ^c   Regazzi, Ashley M ^c   Choueiri, Toni K ^d   Qu, Angela Q ^d   Niegisch, Guenter ^e   Albers, Peter ^e   Necchi, Andrea ^f   Di Lorenzo, Giuseppe ^g   Fougeray, Ronan ^h   Dreicer, Robert ⁱ   Chen, Yu Hui ^d   Wong, Yu Ning ^j   Sridhar, Srikala S ^k   Ko, Yoo Joung ^l   Milowsky, Matthew I ^m   Galsky, Matthew D ⁿ   Bellmunt, Joaquim ^d,o  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h INSTITUT DE RECHERCHE PIERRE FABRE   (France)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j FOX CHASE CANCER CENTER   (United States)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^m UNIVERSITY OF NORTH CAROLINA   (United States)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^o HOSPITAL DEL MAR   (Spain)

more..

Author keywords

Advanced urothelial carcinoma; Complete response; Overall survival; Partial response; Progression free survival; Salvage systemic therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EVEROLIMUS; GEMCITABINE; HEMOGLOBIN; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; VANDETANIB; VINFLUNINE; VOLASERTIB; BIOLOGICAL PRODUCT;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCORTICOGRAPHY; FEMALE; HUMAN; INCIDENCE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR; SALVAGE THERAPY; SYSTEMIC THERAPY; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; AGED; DISEASE FREE SURVIVAL; DRUG EFFECTS; MORTALITY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PROCEDURES; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

AGED; BIOLOGICAL PRODUCTS; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84924598815     PISSN: 15587673     EISSN: 19380682     Source Type: Journal    
DOI: 10.1016/j.clgc.2014.09.004     Document Type: Article

References (32)

1. G. Sonpavde, C.N. Sternberg, J.E. Rosenberg, N.M. Hahn, M.D. Galsky, and N.J. Vogelzang Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium Lancet Oncol 11 2010 861 870
2. J. Bellmunt, C. Theodore, and T. Demkov Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract J Clin Oncol 27 2009 4454 4461
3. A. Necchi, L. Mariani, and N. Zaffaroni Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial Lancet Oncol 13 2012 810 816
4. C.J. Sweeney, B.J. Roth, and F.F. Kabbinavar Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium J Clin Oncol 24 2006 3451 3457
5. Y.N. Wong, S. Litwin, and D. Vaughn Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma J Clin Oncol 30 2012 3545 3551
6. Y.J. Ko, C.M. Canil, and S.D. Mukherjee Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study Lancet Oncol 14 2013 769 776
7. T.K. Choueiri, R.W. Ross, and S. Jacobus Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer J Clin Oncol 30 2012 507 512
8. G. Iyer, A.J. Hanrahan, and M.I. Milowsky Genome sequencing identifies a basis for everolimus sensitivity Science 338 2012 221
9. N. Wagle, B.C. Grabiner, and E.M. Van Allen Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib Cancer Discov 4 2014 546 553
10. D.J. Vaughn, S. Srinivas, and W.M. Stadler Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: results of a large phase 2 study Cancer 115 2009 4110 4117
11. P. Albers, S.I. Park, and G. Niegisch Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99] Ann Oncol 22 2011 288 294
12. Y.N. Wong, S. Litwin, and D. Vaughn Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma J Clin Oncol 30 2012 3545 3551
13. D.J. Gallagher, M.I. Milowsky, and S.R. Gerst Phase II study of sunitinib in patients with metastatic urothelial cancer J Clin Oncol 28 2010 1373 1379
14. M.I. Milowsky, G. Iyer, and A.M. Regazzi Phase II study of everolimus in metastatic urothelial cancer BJU Int 112 2013 462 470
15. G. Di Lorenzo, V. Montesarchio, and R. Autorino Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients Cancer 115 2009 517 523
16. Stadler WM, Vaughn DJ, Sonpavde G, et al. An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. In press.
17. R. Dreicer, H. Li, and M. Stein Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group Cancer 115 2009 4090 4095
18. S. Culine, C. Theodore, and M. De Santis A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen Br J Cancer 94 2006 1395 1401
19. G. Sonpavde, G.R. Pond, and R. Fougeray Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials Eur Urol 63 2013 717 723
20. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
21. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
22. Pond GR, Agarwal N, Bellmunt J, et al. A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma. BJU Int. In press.
23. J. Bellmunt, T.K. Choueiri, and R. Fougeray Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens J Clin Oncol 28 2010 1850 1855
24. G.R. Pond, J. Bellmunt, and R. Fougeray Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design Clin Genitourin Cancer 11 2013 495 500
25. N. Agarwal, J. Bellmunt, and B.L. Maughan Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma Clin Genitourin Cancer 12 2014 130 137
26. J. Bellmunt, L. Paz-Ares, and M. Cuello Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy Ann Oncol 18 2007 522 528
27. J.E. Rosenberg, E.M. Van Allen, and K.W. Mouw Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma J Clin Oncol 32 2014 5(suppl): abstract 4510
28. E.R. Plimack, R. Dunvrack, and T. Brennan Next-generation sequencing to identify molecular alterations in DNA repair and chromatin maintenance genes associated with pathologic complete response to neoadjuvant accelerated methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer J Clin Oncol 32 2014 5(suppl): abstract 4538
29. A. Necchi, M. Pennati, and N. Zaffaroni Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy Br J Cancer 110 2014 26 33
30. T. Powles, N. Vogelzang, and G.D. Fine Inhibition of PD-L1 by MPDL3280A and clinical activity in patients with metastatic urothelial bladder cancer J Clin Oncol 32 2014 5(suppl): abstract 5011
31. Comprehensive molecular characterization of urothelial bladder carcinoma Nature 507 2014 315 322
32. E.S. Kim, R.S. Herbst, and Wistuba II The BATTLE trial: personalizing therapy for lung cancer Cancer Discov 1 2011 44 53